EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma

Isabelle Bergiers iD, Murat Cem Köse iD, Sheri Skerget, Milan Malfait iD, Nele Fourneau iD, Jenna-Claire Ellis iD, Greet Vanhoof, Tina Smets, Bie Verbist, Dries De Maeyer iD, Jeroen Van Houdt, Koen Van der Borght und 12 weitere

PLOS Genetics · 07.10.2025 · 21 (10) · e1011848

DOI: 10.1371/journal.pgen.1011848 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Genetics, online erschienen am 07.10.2025. Verfasst von Isabelle Bergiers und 23 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, Beerse, Belgium. Hauptthemen laut MEDLINE: Multiple Myeloma, Tumor Microenvironment. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Research & Development LLC, Flanders Innovation & Entrepreneurship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Investigation of the cellular and molecular mechanisms of disease progression from precursor plasma cell disorders to active disease increases our understanding of multiple myeloma (MM) pathogenesis and supports the development of novel therapeutic strategies. In this analysis, single-cell RNA sequencing, surface protein profiling, and B lymphocyte antigen receptor profiling of unsorted, whole bone marrow (BM) mononuclear cell samples was used to study molecular changes in tumor cells and the tumor microenvironment (TME). A cell atlas of the BM microenvironment was generated from 123 subjects including healthy volunteers and patients with monoclonal gammopathy of unknown significance (MGUS), smoldering MM (SMM), and MM. These analyses revealed commonalities in molecular pathways, including MYC signaling, E2F targets and interferon alpha response, that were altered during disease progression. Evidence of early dysregulation of the immune system in MGUS and SMM, which increases and impacts many cell types as the disease progresses, was found. In parallel with disease progression, population shifts in CD8 + T cells, macrophages, and classical dendritic cells were observed, and the resulting differences in CD8 + T cells and macrophages were associated with poor overall survival outcomes. Potential ligand-receptor interactions that may play a role during the transition from precursor stages to MM were identified, along with potential biomarkers of disease progression, some of which may represent novel therapeutic targets. MIF, IL15, CD320, HGF and FAM3C were detected as potential regulators of the TME by plasma cells, while SERPINA1 and BAFF (TNFSF13B) were found to have the highest potential to contribute to the downstream changes observed between precursor stage and MM cells. These findings demonstrate that myeloma tumorigenesis is associated with dysregulation of molecular pathways driven by gradually occurring immunophenotypic changes in the tumor and TME. Trial registration: This project has been registered at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) with protocol number NOPRODMMY0001 and EudraCT Number 2018-004443-23 on 12 December 2018.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaTumor MicroenvironmentHumansDisease ProgressionMonoclonal Gammopathy of Undetermined SignificanceImmunophenotypingMaleFemaleMiddle AgedCD8-Positive T-LymphocytesAgedMacrophagesSmoldering Multiple Myeloma

Autor:innen und Institutionen

  • Johnson & Johnson, Beerse, Belgium.
  • Department of Hematology, CHU of Liège, Liège, Belgium.
  • Johnson & Johnson, Spring House, Spring House, Pennsylvania, United States of America.
  • Department of Applied Mathematics, Computer Science and Statistics, University of Ghent, Ghent, Belgium.
  • Department of Orthopedic Surgery, CHU de Liège, Liège, Belgium.
  • University Hospital Leuven, Leuven, Belgium.

ORCID-Profile: Isabelle Bergiers, Murat Cem Köse, Milan Malfait, Nele Fourneau, Jenna-Claire Ellis, Dries De Maeyer, Nizar Bahlis, Jo Caers

Förderung

  • Janssen Research & Development LLC
  • Flanders Innovation & Entrepreneurship

Zitieren

APA

Bergiers, I., Köse, M. C., Skerget, S., Malfait, M., Fourneau, N., Ellis, J. C., Vanhoof, G., Smets, T., Verbist, B., De Maeyer, D., Van Houdt, J., Van der Borght, K., Verona, R., Heidrich, B., Kurth, W., Delforge, M., Meuleman, N., Van Droogenbroeck, J., Vlummens, P., …, & Caers, J. (2025). Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma. PLOS Genetics, 21(10), e1011848. https://doi.org/10.1371/journal.pgen.1011848

Vancouver

Bergiers I, Köse MC, Skerget S, Malfait M, Fourneau N, Ellis JC, et al. Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma. PLOS Genetics. 2025;21(10):e1011848. doi:10.1371/journal.pgen.1011848

BibTeX
@article{Bergiers2025,
  author = {Bergiers, Isabelle and Köse, Murat Cem and Skerget, Sheri and Malfait, Milan and Fourneau, Nele and Ellis, Jenna-Claire and Vanhoof, Greet and Smets, Tina and Verbist, Bie and De Maeyer, Dries and Van Houdt, Jeroen and Van der Borght, Koen and Verona, Raluca and Heidrich, Bradley and Kurth, William and Delforge, Michel and Meuleman, Nathalie and Van Droogenbroeck, Jan and Vlummens, Philip and Heuck, Christoph J and Beguin, Yves and Bahlis, Nizar and Casneuf, Tineke and Caers, Jo},
  title = {Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma},
  journal = {PLOS Genetics},
  year = {2025},
  volume = {21},
  number = {10},
  pages = {e1011848},
  doi = {10.1371/journal.pgen.1011848}
}
Kostenlos starten →